Welcome to our dedicated page for Gilead Sciences SEC filings (Ticker: GILD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Gilead Sciences, Inc. (Nasdaq: GILD) is a Delaware‑incorporated biopharmaceutical company whose common stock is registered on The Nasdaq Global Select Market. As an SEC‑reporting issuer, Gilead files a range of regulatory documents that provide detailed insight into its financial condition, governance and material events. This page aggregates GILD’s SEC filings and pairs them with AI‑generated summaries to help readers understand the key points in complex disclosures.
For Gilead, Form 10‑K annual reports and Form 10‑Q quarterly reports are central sources of information on its HIV, viral hepatitis, COVID‑19, oncology and inflammation businesses, including segment discussions, risk factors and research and development spending. Form 8‑K current reports capture specific developments such as quarterly financial results, amendments to bylaws, executive leadership changes and significant agreements. Recent 8‑K filings, for example, have disclosed financial results for particular quarters, updates to the company’s bylaws governing director nominations and stockholder proposals, patent settlements related to Biktarvy, and changes in senior corporate affairs and legal roles.
Investors can also use this page to access proxy statements for information on board structure and executive compensation, and Form 4 insider transaction reports to track trades by directors and officers. Because Gilead is not classified as an emerging growth company, its filings follow the full disclosure requirements applicable to large, established issuers.
Stock Titan enhances GILD filings with AI‑powered explanations that highlight material items, translate technical accounting and legal language into plain terms, and surface topics such as governance changes, litigation updates or collaboration agreements. Real‑time ingestion from EDGAR means new Gilead filings appear quickly, while the AI layer helps readers focus on what changed, why it matters for the company’s HIV, antiviral and oncology franchises, and how it may affect shareholders.
Gilead Sciences, Inc., through its wholly owned subsidiary Ravens Sub, Inc., is offering to purchase all outstanding shares of Arcellx, Inc. at $115.00 per share in cash plus one contingent value right (CVR) that may pay $5.00 on March 31, 2030 if cumulative worldwide sales of anito-cel exceed $6.0 billion on or prior to December 31, 2029.
The amendment states that all required regulatory approvals under the merger agreement have been obtained and the offer expiration was extended to 5:00 p.m. Eastern Time on April 27, 2026. As of 4:00 p.m. ET on April 16, 2026, approximately 10,271,823 shares were validly tendered and not withdrawn, representing about 17.5% of outstanding shares.
Gilead Sciences, Inc., through its wholly owned subsidiary Ravens Sub, Inc., is offering to purchase all outstanding shares of Arcellx, Inc. at $115.00 per share in cash plus one contingent value right (CVR) that may pay $5.00 on March 31, 2030 if cumulative worldwide sales of anito-cel exceed $6.0 billion on or prior to December 31, 2029.
The amendment states that all required regulatory approvals under the merger agreement have been obtained and the offer expiration was extended to 5:00 p.m. Eastern Time on April 27, 2026. As of 4:00 p.m. ET on April 16, 2026, approximately 10,271,823 shares were validly tendered and not withdrawn, representing about 17.5% of outstanding shares.
Gilead Sciences’ Chief Financial Officer Andrew D. Dickinson reported an open-market sale of company stock. On this Form 4, he sold 3,000 shares of Gilead Sciences common stock at a price of $140.96 per share.
The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 29, 2024, indicating it was scheduled in advance. Following this sale, Dickinson continues to hold 176,191 shares of Gilead Sciences common stock directly.
Gilead Sciences, Inc. executive Johanna Mercier, Chief Commercial & Corporate Affairs Officer, sold 3,000 shares of common stock at $140.96 per share in an open-market transaction. After this sale, she directly holds 128,779 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 20, 2025, indicating the timing was set in advance.
Johanna Mercier reported sales of restricted common stock. The filing lists two completed dispositions: 28,000 shares sold on 02/17/2026 for $4,324,227.70 and 3,000 shares sold on 03/16/2026 for $432,690.00. The form also lists restricted stock entries dated 12/10/2024 (1,519 shares) and 09/10/2024 (1,481 shares) as securities to be sold.
The transactions are reported on a Form 144-style disclosure and show sales by an individual filing. The filing records trade dates and gross proceeds for each completed sale; additional timing or proceeds treatment for the restricted shares listed to be sold is not provided in the excerpt.
Morgan Stanley Smith Barney LLC notice of proposed sale under Form 144 relating to 3,000 common shares described as Performance Shares dated 01/24/2023. The filing lists two prior sales by Andrew Dickinson: 3,000 shares on 03/16/2026 for $432,690 and 3,000 shares on 02/17/2026 for $463,290.
Ravens Sub, Inc., a wholly owned subsidiary of Gilead Sciences, Inc., amended its Schedule TO to report results and updates to its tender offer for all outstanding shares of Arcellx, Inc. The Offer pays $115.00 per share in cash plus one contingent value right (a CVR) that may pay $5.00 on March 31, 2030 if cumulative worldwide sales of anito-cel exceed $6.0 billion on or prior to December 31, 2029. The HSR waiting period expired on March 31, 2026. As of 5:00 p.m. ET on March 31, 2026, approximately 4,389,763 shares (about 7.5% of outstanding) were validly tendered. Parent extended the Offer expiration to 5:00 p.m. ET on April 24, 2026. The filing discloses related antitrust notifications in Germany, Austria and Australia and two New York stockholder lawsuits and multiple demand letters alleging disclosure deficiencies.
Gilead Sciences Chairman & CEO Daniel O'Day reported an open-market sale of 10,000 shares of Common Stock on 2026-03-27 at an average price of $136.8162 per share. The transaction was made under a Rule 10b5-1 trading plan adopted on 2025-02-28, with sale prices ranging from $136.51 to $137.22. Following this sale, he continues to directly hold 642,567 shares of Gilead Sciences common stock.
GILD reporting person Daniel O'Day filed a Form 144 reporting proposed sales of Common shares. The filing lists multiple dispositions by Mr. O'Day, with examples shown including a 02/05/2026 sale of 115,640 shares for $17,346,000 and a 01/23/2026 sale of 115,640 shares for $15,611,400. The notice names Morgan Stanley Smith Barney LLC as the broker.
Gilead Sciences Inc filing shows an amended Schedule 13G/A from The Vanguard Group reporting that, after an internal realignment, Vanguard and certain subsidiaries will report holdings separately and that The Vanguard Group beneficially owns 0 shares of Common Stock (0%).
The amendment explains the disaggregation is made in accordance with SEC Release No. 34-39538 and states related subsidiaries pursue the same investment strategies previously used; signature dated 03/26/2026.